Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) is a clinical-stage biotechnology company focused on the discovery and development of novel monoclonal antibodies and immunotherapies to treat life-threatening bacterial and viral infections. The company’s technology harnesses the body’s immune system to target and neutralize pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa, which are commonly associated with hospital-acquired pneumonia and other severe infectious diseases. Aridis emphasizes antibody engineering and protein optimization to create treatments with enhanced specificity, potency and reduced potential for antibiotic resistance.
The company’s lead programs include AR-301, a monoclonal antibody targeting alpha toxin produced by Staphylococcus aureus to mitigate ventilator-associated pneumonia, and AR-105 (panobacumab), designed to neutralize Pseudomonas aeruginosa in patients with nosocomial gram-negative infections. Both candidates have advanced through Phase 1 and Phase 2 clinical evaluations, demonstrating favorable safety profiles and biological activity. In addition, Aridis is advancing a broader pipeline of next-generation immunotherapies and antibody cocktails aimed at combating emerging drug-resistant bacterial strains and viral pathogens beyond traditional small-molecule antibiotics.
Founded in 2016 and headquartered in San Jose, California, Aridis Pharmaceuticals operates as a publicly traded company listed on NASDAQ under the ticker ARDS. The firm maintains strategic partnerships with academic research institutions and global contract research organizations to accelerate preclinical and clinical development. While its primary operations focus on the North American market, Aridis has established international research collaborations and out-licensing frameworks to enable potential commercialization in Europe, Asia and other regions facing rising antibiotic resistance challenges.
Led by a seasoned management team with extensive experience in biologics, infectious disease research and pharmaceutical strategy, Aridis is governed by a board of directors that includes former biotech executives and academic scientists. This leadership cohort brings deep expertise in clinical development, regulatory affairs and commercial planning, positioning Aridis as an innovator in the evolving field of immunotherapies for critical unmet medical needs in infectious diseases.
AI Generated. May Contain Errors.
Free ARDS Stock Alerts